Trevi Therapeutics stock hits all-time high at 19.33 USD

Trevi Therapeutics (TRVI) hit an all-time high near $19.33 and has surged 226.05% over the past 12 months, though InvestingPro flags the shares as overvalued vs fair value. The company reported Q1 2026 results with a pro forma cash balance of about $334M after an April offering, targeting operations through 2030. Trevi plans to start its pivotal Haduvio program in IPF-CC this quarter following an FDA end-of-Phase-2 meeting, with first data expected in 2027, while Stifel reaffirmed a Buy rating and $18 price target.

Analysis

TRVI’s setup is now less about financing survival and more about how much optionality the market is willing to pay for a long-dated, binary catalyst. A balance sheet that runs to 2030 removes the usual microcap biotech discount, which is why the stock can keep rerating even before pivotal data; that said, once dilution risk is largely gone, valuation becomes much more sensitive to protocol execution and enrollment quality than to cash balance headlines.

The second-order effect is that capital is rotating toward “clean” clinical names where cash runway and regulatory path are visible, leaving weaker balance-sheet peers with no comparable near-term catalyst vulnerable to relative underperformance. The current move also suggests the market is willing to pay for scarcity value in a crowded biotech tape, but that tends to be fragile: if the first pivotal milestones don’t show clean operational execution, the multiple can compress quickly because there is no data readout until 2027 to anchor the story.

The contrarian point is that the street may be underestimating opportunity cost and overestimating the value of de-risking alone. With the first meaningful efficacy data still years away, the stock can drift on sentiment and momentum rather than fundamentals, which argues for tactical rather than strategic exposure. NDAQ’s weakness here is just a risk-off read-through, not a company-specific signal; the real trade is whether investors are paying too much for a long-duration biotech option before any measurable clinical payoff.

Key Decisions for Investors

• Do not chase TRVI at all-time highs; wait for a 10-15% pullback or for trial-initiation details before considering entry, because the upside is mostly multiple expansion and the downside on any execution slip is abrupt.
• If expressing a view, use a small-size TRVI 2027 call spread only after protocol/timing confirmation; the thesis is limited dilution risk through 2030, but the trade should be sized as a long-dated option rather than a core equity position.
• Consider a relative-value long TRVI / short basket of cash-burner pre-data biotechs with weaker balance sheets; the edge is not the asset itself but the financing runway differential and lower near-term dilution risk.
• Set an alert on any slip in pivotal start, enrollment pace, or endpoint design changes; those are the key falsifiers and would matter more than day-to-day price action.
• Treat NDAQ and the broader Nasdaq weakness as tape noise unless it widens into a sustained growth-factor de-rating, in which case beta-heavy biotech multiple expansion is likely to stall first.